Description
Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated
Affinity’s Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated is the highest level of our biotin conjugated Factor VII antibodies. During the Antigen Affinity Purification process the IgG has had any non-specific immunoglobulin fraction eliminated which enriches the specificity of the remaining immunoglobulin towards the target antigen. The result is a very high-purity product with a substantially higher titre than whole or purified IgG. Our Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v) and has been conjugated with Biotin as an enzyme reporter. This antibody is generally intended for use as labelled primary antibodies in applications such as immunoassay and immunoblotting.
Product Code: SAFVII-APBIO
Retail Product Size: 0.1mg vial
Host Animal: Sheep Anti-Human Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated
Species Cross Reactivity: View Chart
Product Datasheet: Factor VII F7 Polyclonal Antibody - biotin conjugated anti-human sheep IgG
Description of Factor VII
Factor VII (FVII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of FVII is normally ~0.5 μg/ml (10 nM) in plasma. A deficiency of FVII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in FVII function. In its zymogen form FVII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 γ-carboxyglutamic acid (Gla) residues. These Gla residues allow FVII to bind divalent metal ions and participate in calcium-dependent binding interactions. FVII and activated FVII (FVIIa) bind to tissue factor exposed at the site of vascular injury. FIXa, FXa or FVIIa rapidly activate tissue factor-bound FVII to FVIIa in the presence of calcium and phospholipid. Thrombin and FXIIa are able to activate FVII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen FVII occurs by proteolysis after residue Arg152, resulting in a two-chain active serine protease consisting of a 30 kDa heavy chain and a 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, FVIIa is able to activate F.X and F.IX. Free FVIIa in plasma is remarkably stable, but the activity of FVIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa, and also by Antithrombin (ATIII) in the presence of heparin1-3.
References and Reviews
1. Rao LVM, Bajaj SP, Rapaport SI; Activation of Human Factor VII During Clotting in Vitro; Blood 65, pp 218-226, 1985.
2. Lawson, JH, Butenas S, Ribarik N, Mann KG; Complex-dependent Inhibition of Factor VIIa by Antithrombin III and Heparin; JBC 268 pp 767-770, 1993.
3. Nemerson Y, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA, 1994.
Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated
SAFVII-APBIO – Sheep anti human Factor VII, affinity purified, Biotinylated IgG (0.1 mg vial)
Description
Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated
Affinity’s Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated is the highest level of our biotin conjugated Factor VII antibodies. During the Antigen Affinity Purification process the IgG has had any non-specific immunoglobulin fraction eliminated which enriches the specificity of the remaining immunoglobulin towards the target antigen. The result is a very high-purity product with a substantially higher titre than whole or purified IgG. Our Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v) and has been conjugated with Biotin as an enzyme reporter. This antibody is generally intended for use as labelled primary antibodies in applications such as immunoassay and immunoblotting.
Product Code: SAFVII-APBIO
Retail Product Size: 0.1mg vial
Host Animal: Sheep Anti-Human Factor VII Polyclonal Antibody – Affinity Purified – Biotinylated
Species Cross Reactivity: View Chart
Product Datasheet: Factor VII F7 Polyclonal Antibody - biotin conjugated anti-human sheep IgG
Description of Factor VII
Factor VII (FVII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of FVII is normally ~0.5 μg/ml (10 nM) in plasma. A deficiency of FVII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in FVII function. In its zymogen form FVII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 γ-carboxyglutamic acid (Gla) residues. These Gla residues allow FVII to bind divalent metal ions and participate in calcium-dependent binding interactions. FVII and activated FVII (FVIIa) bind to tissue factor exposed at the site of vascular injury. FIXa, FXa or FVIIa rapidly activate tissue factor-bound FVII to FVIIa in the presence of calcium and phospholipid. Thrombin and FXIIa are able to activate FVII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen FVII occurs by proteolysis after residue Arg152, resulting in a two-chain active serine protease consisting of a 30 kDa heavy chain and a 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, FVIIa is able to activate F.X and F.IX. Free FVIIa in plasma is remarkably stable, but the activity of FVIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa, and also by Antithrombin (ATIII) in the presence of heparin1-3.
References and Reviews
1. Rao LVM, Bajaj SP, Rapaport SI; Activation of Human Factor VII During Clotting in Vitro; Blood 65, pp 218-226, 1985.
2. Lawson, JH, Butenas S, Ribarik N, Mann KG; Complex-dependent Inhibition of Factor VIIa by Antithrombin III and Heparin; JBC 268 pp 767-770, 1993.
3. Nemerson Y, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA, 1994.